tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CH:BIOV Stock Latest News

BioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
Company AnnouncementsBioVersys Advances BV100 Into Phase IIb for Drug-Resistant Hospital Infections
1d ago
BIOV
BioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
PremiumCompany Announcements
BioVersys gains key TB proof-of-concept as AlpE Phase 2a data land in NEJM
6d ago
BIOV
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
PremiumCompany Announcements
BioVersys Advances BV100 Into Phase 3 For Drug-Resistant Hospital Pneumonia: What Investors Should Watch
2M ago
BIOV
BioVersys AG Launches BV100 Phase 3 and Strengthens Market Position
PremiumCompany Announcements
BioVersys AG Launches BV100 Phase 3 and Strengthens Market Position
3M ago
BIOV
BioVersys’ BV100 Selected for Phase 2b Trial in Southeast Asia
PremiumCompany Announcements
BioVersys’ BV100 Selected for Phase 2b Trial in Southeast Asia
4M ago
BIOV
BioVersys Initiates Phase 1 Trial of BV100 in China to Combat Drug-Resistant Infections
PremiumCompany AnnouncementsBioVersys Initiates Phase 1 Trial of BV100 in China to Combat Drug-Resistant Infections
4M ago
BIOV
BioVersys to Present Developments at Stifel 2025 Healthcare Conference
Premium
Company Announcements
BioVersys to Present Developments at Stifel 2025 Healthcare Conference
4M ago
BIOV
BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer
Premium
Company Announcements
BioVersys Appoints Dr. Daniel Ritz as Chief Scientific Officer
4M ago
BIOV
BioVersys AG Reports Key Financials and Clinical Progress for H1 2025
PremiumCompany Announcements
BioVersys AG Reports Key Financials and Clinical Progress for H1 2025
6M ago
BIOV
BioVersys AG to Announce Half-Year 2025 Financial Results and Host Conference Call
PremiumCompany Announcements
BioVersys AG to Announce Half-Year 2025 Financial Results and Host Conference Call
6M ago
BIOV
BioVersys Secures EMA Orphan Designation for Tuberculosis Treatment
PremiumCompany Announcements
BioVersys Secures EMA Orphan Designation for Tuberculosis Treatment
6M ago
BIOV
BioVersys Partners with Shionogi for NTM Clinical Candidate Development
PremiumCompany Announcements
BioVersys Partners with Shionogi for NTM Clinical Candidate Development
8M ago
BIOV
BioVersys AG Reports Positive AGM Outcomes and Strategic Advancements
PremiumCompany AnnouncementsBioVersys AG Reports Positive AGM Outcomes and Strategic Advancements
8M ago
BIOV
BioVersys AG Announces 2025 AGM and Board Changes
Premium
Company Announcements
BioVersys AG Announces 2025 AGM and Board Changes
9M ago
BIOV
BioVersys to Host Event on Promising BV100 Pneumonia Treatment
Premium
Company Announcements
BioVersys to Host Event on Promising BV100 Pneumonia Treatment
10M ago
BIOV
BioVersys AG to Showcase Promising BV100 Data at ESCMID Global 2025
PremiumCompany Announcements
BioVersys AG to Showcase Promising BV100 Data at ESCMID Global 2025
11M ago
BIOV
BioVersys Secures Key Patent in China for BV100 Drug
PremiumCompany Announcements
BioVersys Secures Key Patent in China for BV100 Drug
11M ago
BIOV
BioVersys AG: Positioned for Growth with Strong Financials and Promising Pipeline
PremiumRatings
BioVersys AG: Positioned for Growth with Strong Financials and Promising Pipeline
11M ago
BioVersys AG Achieves Key Milestones in 2024 with Successful IPO and Promising Clinical Results
PremiumCompany Announcements
BioVersys AG Achieves Key Milestones in 2024 with Successful IPO and Promising Clinical Results
11M ago
BIOV
BioVersys and GSK Advance Tuberculosis Treatment with New Clinical Trial
PremiumCompany AnnouncementsBioVersys and GSK Advance Tuberculosis Treatment with New Clinical Trial
11M ago
BIOV
BioVersys AG Sets Date for 2024 Financial Results Announcement
Premium
Company Announcements
BioVersys AG Sets Date for 2024 Financial Results Announcement
12M ago
BIOV
BioVersys AG Partially Exercises Over-Allotment Option Post-IPO
Premium
Company Announcements
BioVersys AG Partially Exercises Over-Allotment Option Post-IPO
12M ago
BIOV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >